Investigational Gout Drugs Do Well in Clinical Trials
Two major American drug companies are racing to get rival new gout medications to market. Both gout medicines take novel approaches to treating refractory gout - gout that hasn't already responded well to current treatment.
Ardea Biosciences had been the first one to announce productive clinical trials of its experimental gout drug RDEA594, also known as Lesinurad. Lesinurad's mechanism of action is different from that of the commonly prescribed xanthine oxidase inhibitors gout medications (such as allopurinol and febuxostat), which decrease the development of uric acid.
Lesinurad is often a URAT1 transporter inhibitor which boosts refraining from uric acid with the kidneys. Lesinurad is also active against another important regulator of urate secretion, OAT4. OAT4 is thought to be responsible for the high uric acid levels in gouty arthritis patients whose condition is caused or worsened by diuretics.
The Lesinurad study involved 208 gout patients who had high blood urate levels for at least A few months, even while taking the gout drug allopurinol. Individuals continued on allopurinol and were randomly assigned to receive either a placebo or lesinurad at doses of 200 mg, 400 mg, or 600 mg for four weeks.
All three groups who were given lesinurad showed significantly lower uric acid levels at the end of the month. The percentage of patients who achieved the target for uric acid levels after treatment was 28% in the placebo group, 71% in the 200 mg group, 76% in the 400 mg party, and 87% in the 600 mg group.
More not too long ago, explains to you of BioCryst Pharmaceuticals rose 12% upon the release of the results of its phase 2b randomized, double-blind, study of the investigational gout drug BCX4208. BCX4208 is often a novel enzyme inhibitor that acts upstream of xanthine oxidase in the purine metabolism path to reduce serum uric acid (sUA).
Its mechanism of action complements xanthine oxidase inhibitors such as allopurinol and febuxostat in reducing uric acid production, and BCX4208 is intended as an add-on therapy for those gouty arthritis patients who will not respond well to current gout medication.
Like Lesinurad, BCX4208 was studied in gouty arthritis patients who had experienced high blood urate levels for at least 6 months, despite taking the gout drug allopurinol. The 279 study participants were randomly assigned to take BCX4208 at doses of either 5 mg, 10 mg, 20 mg, or 40 mg once daily for 12 weeks. One group of sufferers was given a placebo. All participants were also given allopurinal 300 mg once-daily.
- All but one of the doses showed that BCX4208 was superior to the placebo when used with allopurinol.
- The BCX4208 doses examined in the study showed response rates ranging from 33% to 49%, compared to 18% for those taking the placebo.
At this point, Lesinurad appears the more promising of the two gout medications, and the most likely to hit the market first. This outperformed BCX4208 in early clinical trials, and is farther forward in the development and approval process. But individual responses in order to drugs vary, and gout patients will benefit from having two new approaches to relieving the symptoms of this painful condition.
How to Cure Gout Naturally - Simple Gout Treatment at Home - Home Remedies for Gout
http://homeyog.com This video shows how to cure gout naturally at home. The gout treatment mentioned in the video is a very old one and has been used for ...
Alex Ray Advocates With Regard to Affordable Access to Healthcare and Medication
She recommends Big Mountain Drugs as a trusted on the internet Canadian pharmacy from which to buy allopurinol and colchicine for gout. For more information about gout and gout medication, go to the on the internet reference www.colchicine.ca.